Move to topTop
May 05, 2020

Terumo Aortic today announced that the US Food and Drug Administration (FDA) has granted approval of the TREO™ Abdominal Aortic Stent-Graft System for sale in the United States for the treatment of patients with abdominal aortic aneurysms (AAA).

TREO is the only device commercially available for endovascular aneurysm repair (EVAR) with dual proximal fixation and lock stent technology offering physicians the next advancement in endovascular device solutions. It is a three-piece design featuring in situ limb adjustability and provides a wide range of aortic device configurations to specifically address the anatomy of each individual patient. TREO is designed for accurate, controlled and safe deployment; the exclusive proximal clasping mechanism and a unique leave-behind sheath simplify the procedure as highlighted in recent clinical studies.

Scott Rush, Terumo Aortic's Vice President of Research and Development said, "We set out to provide a AAA system with the most comprehensive set of benefits available and believe that we have an implant and delivery system that is unmatched in terms of design features. The tri-modular design and in situ sizing of TREO allow physicians to deliver a tailored solution by selecting components precisely sized and joined for each patient's anatomy."

"Stent migration and endoleaks are major concerns in EVAR," said Matt Eagleton, MD (Boston, MA), the National Principal Investigator of the IDE Study. "The TREO stent-graft offers both suprarenal and infrarenal fixation, distributing the stent-graft fixation in two different anatomical levels which may work to reduce potential migration. I have been very impressed with the results of the trial, particularly in the sac shrinkage data. I expect this to lower re-intervention rates in my practice."

Paul Kuznik, President of Terumo Aortic North America, commented, "This approval represents a tremendous opportunity for Terumo Aortic in the United States. We recently complemented our sales organisation with our open surgical graft portfolio and now, with the addition of TREO, we are shaping up to be one of the strongest companies within the aortic space fulfilling our commitment to find solutions for every aorta."

TREO received CE Mark approval in 2015 and is integral to Terumo Aortic's market-leading portfolio of surgical, endovascular and hybrid devices to treat every segment of the aorta.

  • 20200505.jpg

About Terumo Aortic

At Terumo Aortic, our mission is to transform the treatment of aortic disease worldwide. With our comprehensive portfolio of surgical, endovascular and hybrid technologies, we enable surgeons to find the right fit for each patient anatomy.

About Terumo

Terumo (TSE: 4543) is a global leader in medical technology and has been committed to “Contributing to Society through Healthcare” for 100 years. Based in Tokyo and operating globally, Terumo employs more than 28,000 associates worldwide to provide innovative medical solutions in more than 160 countries and regions. The company started as a Japanese thermometer manufacturer, and has been supporting healthcare ever since. Now, its extensive business portfolio ranges from vascular intervention and cardio-surgical solutions, blood transfusion and cell therapy technology, to medical products essential for daily clinical practice such as transfusion systems, diabetes care, and peritoneal dialysis treatments. Terumo will further strive to be of value to patients, medical professionals, and society at large.

Among the information that Terumo discloses, the forward-looking statements including financial projections are based upon our assumptions using information available to us at the time and are not intended to be guarantees of future events or performance. Accordingly, it should be noted that actual results may differ from those forecasts or projections due to various factors. Factors affecting to actual results include, but are not limited to, changes in economic conditions surrounding Terumo, fluctuations of foreign exchange rates, and state of competition.


Information about products (including products currently in development) included in this material is not intended to constitute an advertisement or medical advice.